Celsion Provides Update On Its Global Pivotal Phase III Primary Liver Cancer Trial
Sep 30th 2008Drug InformationLiver Disease / Hepatitis
Celsion Corporation (NASDAQ: CLSN) announced today that its global Phase III Primary Liver Cancer trial is proceeding as planned.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
